ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-16 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 154.7 KB | ||
| 2023-05-15 22:45 |
ERYTECH Provides Update on the Announced Combination with PHERECYDES
|
English | 264.8 KB | ||
| 2023-05-15 22:45 |
Point d'étape sur le rapprochement entre ERYTECH et PHERECYDES
|
French | 205.7 KB | ||
| 2023-05-15 08:00 |
Akkadian Partners Fund has acquired over a 5% shareholding and voting rights in…
|
English | 270.0 KB | ||
| 2023-05-15 08:00 |
Akkadian Partners Fund acquiert une participation supérieure à 5% du capital et…
|
French | 302.2 KB | ||
| 2023-05-12 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions …
|
French | 214.6 KB | ||
| 2023-05-12 18:00 |
Monthly information related to total number of voting rights and shares compos…
|
English | 234.7 KB | ||
| 2023-05-12 18:00 |
Akkadian Partners Fund has acquired over a 5% shareholding and voting rights in…
|
English | 269.9 KB | ||
| 2023-05-12 18:00 |
Akkadian Partners Fund acquiert une participation supérieure à 5% du capital et…
|
French | 280.5 KB | ||
| 2023-05-10 09:50 |
Franchissement de seuil
|
French | 201.9 KB | ||
| 2023-05-09 08:00 |
ERYTECH fait le point sur ses activités et sa position financière pour le premi…
|
French | 291.2 KB | ||
| 2023-05-09 08:00 |
ERYTECH Provides Business and Financial Update for the First Quarter of 2023
|
English | 292.5 KB | ||
| 2023-04-18 10:46 |
Franchissement de seuil
|
French | 201.7 KB | ||
| 2023-04-17 22:05 |
ERYTECH annonce l'approbation du transfert de sa cotation vers le Nasdaq Capita…
|
French | 285.7 KB | ||
| 2023-04-17 22:05 |
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market
|
English | 284.4 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
